Applying the McKinsey 7S Framework to TLL and regional marketing teams.

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective financing rounds.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

The latest news for pharma industry insiders.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.

The Project Farma president discusses various ways the tariffs could impact the industry and how businesses can prepare or react.

Dr. Dina Radenkovic, CEO of Gameto, identifies strategies to close the gap in women's health and how we can better incentivize research and development in this area.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral calcium therapy in chronic hypoparathyroidism.

The latest news for pharma industry insiders.

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology therapies, respectively.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.

The latest news for pharma industry insiders.

Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in women's health innovation.

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26.

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics areas.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

The latest news for pharma industry insiders.

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in pharma investing.

Dr. Dina Radenkovic, CEO of Gameto, discusses the key considerations for bringing iPSC-based fertility treatments to market from a regulatory and manufacturing perspective.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

A look at the current landscape and how young companies can set the stage for product launch.